tiprankstipranks
Blurbs

Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Premier (PINC)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ultragenyx Pharmaceutical (RAREResearch Report), Premier (PINCResearch Report) and AstraZeneca (AZNResearch Report) with bullish sentiments.

Ultragenyx Pharmaceutical (RARE)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Ultragenyx Pharmaceutical on July 28 and set a price target of $115.00. The company’s shares closed last Friday at $53.28, close to its 52-week low of $45.20.

According to TipRanks.com, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -10.6% and a 36.1% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $108.00, representing a 109.7% upside. In a report issued on July 28, Piper Sandler also maintained a Buy rating on the stock with a $130.00 price target.

See today’s best-performing stocks on TipRanks >>

Premier (PINC)

In a report issued on July 28, Stephanie Davis from SVB Securities maintained a Buy rating on Premier. The company’s shares closed last Friday at $38.46.

According to TipRanks.com, Davis is a 1-star analyst with an average return of -1.4% and a 48.5% success rate. Davis covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, NextGen Healthcare, and Change Healthcare.

Premier has an analyst consensus of Moderate Buy, with a price target consensus of $42.75.

AstraZeneca (AZN)

SVB Securities analyst Andrew Berens maintained a Buy rating on AstraZeneca on July 29. The company’s shares closed last Friday at $66.23.

According to TipRanks.com, Berens is ranked 0 out of 5 stars with an average return of -4.6% and a 46.9% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AstraZeneca with a $80.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RARE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More